“I have been a psychiatrist for over 40 years, and to see an intervention that can give people suffering as much as these folks do relief so quickly is unlike almost anything else I have seen” - Scott T. Aaronson
Read the full conversation on our website.
Breaking: Mike Davis has become Acting Director of FDA’s Center for Drug Evaluation and Research (CDER) following the departure of Tracy Beth Høeg.
Davis spent three years as Chief Medical Officer of psilocybin drug developer Usona Institute before returning to FDA as Deputy Director of CDER last Summer. Beth Høeg’s departure comes as FDA Commissioner Marty Makary also resigned earlier this week.
Since launching in 2023, Oregon’s psilocybin program has served an estimated 17,000 clients and sold more than 42,000 psilocybin products, generating over $1.9M in revenue. At the same time, average product prices have dropped from ~$85 in 2023 to ~$51 in Q1 2026 — likely driven by growing competition among licensed manufacturers.
Read more on our website.
IRBs Broadly Neutral on Psychedelics Studies, Survey Finds
A new journal article by Robinson et al. (2026) surveyed 529 IRB chairs to understand their views on psychedelic research. 212 completed at least 80% of their survey. Participants often selected neutral responses regarding their attitudes towards psychedelics, the authors note, with the majority of respondents reporting similar confidence in their ability to review psychedelic and non-psychedelic protocols.
Read more on our website.
We spoke with psychiatrist and researcher Scott T. Aaronson about a new study published today, in which his group administered psilocybin to twenty patients with chronic suicidal ideation.
Read the full conversation on our website.
April 2026 Psychedelic Bill Round-up
April 2026 was a very busy month for psychedelic policy in the U.S., with bills progressing through statehouses or falling to the wayside as legislative sessions began to taper off and action from the very top of the federal government.
More than three dozen psychedelics-related bills saw substantive activity in April across 20 states and at the federal level. Notably, seven became law, two were vetoed in West Virginia, and several others moved one chamber closer to enactment.
Our state-by-state round-up highlights the more significant developments...
Read more on our website.
“When Resilient submits its updated data to the FDA, I hope the FDA prioritizes the review. It is the only program with completed Phase 3 trials for PTSD and is positioned to begin treating patients immediately following approval.” - @genevieve
Read more on our website.
Psychedelic research @robincarhartharris spoke to us about a new study published in Nature Communications that looks at brain changes after first psilocybin use.
Pentagon Details MDMA Study Funding for Active-Duty Service Members
A Report from the U.S. Department of Defense details $9.8 million in funding for two MDMA studies in active-duty service members with PTSD. The first trials MDMA-assisted therapy while the second focuses on MDMA-enhanced massed prolonged exposure. The target enrolment is 196 participants across the two studies, which will take place at Walter Reed National Military Medical Center, the University of Texas, and Emory University.
Read more on our website.
“Thanks to the leadership of Dr. @rachelyehudaphd , more than 250 therapists within the VA are already trained in [MDMA-assisted therapy], with hundreds more trained outside the system. Dr. Yehuda and a team of VA clinicians and researchers are also contributing important new data from VA trials that demonstrate the remarkable efficacy of this treatment.” - @genevieve
Read more on our website.
Pre-EO, DEA Poured Cold Water on Psilocybin Right to Try Project
Letters obtained by Psychedelic Alpha show that the U.S. Drug Enforcement Administration (DEA) emphasised that Right to Try does to waive Controlled Substances Act requirements, pouring cold water on Scottsdale Research Institute’s plans to offer whole mushroom psilocybin through the pathway. But the Institute’s founder, @suesisley , says she will continue to press the agency on this matter, especially in light of the Executive Order.
Read more on our website.
APA Issues Statement on Psychedelics Executive Order
The American Psychiatric Association issued a statement last month, two days after President Trump signed the psychedelics-related executive order. It said it welcomed investment in research into psychedelic therapies for serious mental illness but emphasised that “additional research is necessary.
Read more on our website.
![“Thanks to the leadership of Dr. @rachelyehudaphd, more than 250 therapists within the VA are already trained in [MDMA-assisted therapy], with hundreds more trained outside the system. Dr. Yehuda and a team of VA clinicians and researchers are also contributing important new data from VA trials that demonstrate the remarkable efficacy of this treatment.” - @genevieveRead more on our website.](https://sp1.picnob.com/p/pt_6727411319446741542064_0_d740980b5203fc98b3f9f9f7b82deb87.jpg?o=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&h=032db2457739fa39a67d5b81ccb8a8ba)
